Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-09-21
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices, cloud workflow software, and embedded licensing based on its semiconductor ultrasound platform.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Handheld ultrasound seeks platform economics
A differentiated probe and cloud stack can still compound into a larger imaging workflow and licensing business. The key question is whether recurring software and partner economics become real before the market loses patience with a premium valuation.

Analysis

Thesis
Butterfly can still create a 2x-3x equity outcome by 2031 if it turns a differentiated handheld ultrasound chip into a broader recurring stack of workflow, compliance, home-care utility, and partner royalties, with AI mainly expanding who can scan, where scans happen, and how much value accrues to each deployed device.
Last Economy Alignment
AI lowers the skill barrier to imaging, while Butterfly still controls the probe, cloud workflow, and regulated buyer surface. The company benefits if ultrasound becomes more routine, but it must deepen software and licensing capture faster than handheld hardware becomes easier to copy.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.3x (from 5 most recent analyses)
Reasoning
The upside is mainly a quality-of-revenue story, not just a unit story. More probes help, but the bigger unlock is turning each deployed device into a recurring software, compliance, and partner-licensing node. If Compass, Home & Community Care, and Embedded become repeatable rather than bespoke, the business can support strong equity compounding even with a materially lower sales multiple than today.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The real risk is not whether the probe works; it does. The risk is whether Butterfly can convert that hardware lead into durable recurring economics before partner lumpiness, procurement friction, regulatory gates, and incumbent bundling pull it back toward a conventional small-cap device valuation.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They own a low-cost ultrasound probe, the cloud workflow around it, and some of the compliance plumbing, so AI can help more people scan while keeping Butterfly in the loop. The threat is that bigger imaging companies copy enough of the workflow and that newer channels stay pilots instead of becoming routine care.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$10.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case